EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM)
Publication/Presentation Date
11-2024
Volume
26
Issue
8
First Page
88
Last Page
88
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Surgery
Document Type
Article
COinS